Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy

Cancer Letters

Volumn 307, Issue 1, 2011, Pages 18-25

  Zhou, Lin ^a,b   Zhang, Ruifeng ^c   Zhang, Lianfeng ^a   Yao, Weiyan ^b   Li, Jiansheng ^a   Yuan, Yaozong ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Angiotensin converting enzyme 2 (ACE2); Motility; Pancreatic cancer; Proliferation; Tumorigenesis

Indexed keywords

ADENOVIRUS VECTOR; ANGIOTENSIN CONVERTING ENZYME 2; GEMCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER GROWTH; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANOXIA; ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; PEPTIDYL-DIPEPTIDASE A; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA;

EID: 79957440232     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.011     Document Type: Article

References (40)

1. Sener S.F., Fremgen A., Menck H.R., Winchester D.P. Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the National Cancer Database. J. Am. Coll. Surg. 1999, 189:1-7.
2. DiMagno E.P., Reber H.A., Tempero M.A. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999, 117:1464-1484.
3. Friess H., Ding J., Kleeff J., Fenkell L., Rosinski J.A., Guweidhi A., Reidhaar-Olson J.F., Korc M., Hammer J., Buchler M.W. Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol. Life Sci. 2003, 60:1180-1199.
4. Garcea G., Neal C.P., Pattenden C.J., Steward W.P., Berry D.P. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur. J. Cancer 2005, 41:2213-2236.
5. Hruban R.H. Pancreatic cancer: from genes to patient care. J. Gastrointest. Surg. 2001, 5:583-587.
6. Okami J., Simeone D.M., Logsdon C.D. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res. 2004, 64:5338-5346.
7. Leung P.S., Chappell M.C. A local pancreatic renin-angiotensin system: endocrine and exocrine roles. Int. J. Biochem. Cell Biol. 2003, 35:838-846.
8. Sugimoto M., Furuta T., Shirai N., Ikuma M., Sugimura H., Hishida A. Influences of chymase and angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in Japan. Cancer Epidemiol. Biomarkers Prev. 2006, 15:1929-1934.
9. Greco S., Muscella A., Elia M.G., Salvatore P., Storelli C., Mazzotta A., Manca C., Marsigliante S. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J. Cell Physiol. 2003, 196:370-377.
10. Uemura H., Ishiguro H., Nakaigawa N., Nagashima Y., Miyoshi Y., Fujinami K., Sakaguchi A., Kubota Y. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol. Cancer Ther. 2003, 2:1139-1147.
11. Arrieta O., Guevara P., Escobar E., Garcia-Navarrete R., Pineda B., Sotelo J. Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br. J. Cancer 2005, 92:1247-1252.
12. Deshayes F., Nahmias C. Angiotensin receptors: a new role in cancer?. Trends Endocrinol. Metab. 2005, 16:293-299.
13. H.A. Arafat, Q. Gong, G. Chipitsyna, A. Rizvi, C.T. Saa, C.J. Yeo, Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma, J. Am. Coll. Surg. 204 (2007) 996-1005 (discussion 1005-1006).
14. Egami K., Murohara T., Shimada T., Sasaki K., Shintani S., Sugaya T., Ishii M., Akagi T., Ikeda H., Matsuishi T., Imaizumi T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest. 2003, 112:67-75.
15. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R., Breitbart R.E., Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000, 87:E19.
16. Koka V., Huang X.R., Chung A.C., Wang W., Truong L.D., Lan H.Y. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am. J. Pathol. 2008, 172:1174-1183.
17. Mizuiri S., Hemmi H., Arita M., Ohashi Y., Tanaka Y., Miyagi M., Sakai K., Ishikawa Y., Shibuya K., Hase H., Aikawa A. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am. J. Kidney Dis. 2008, 51:613-623.
18. Raizada M.K., Ferreira A.J. ACE2: a new target for cardiovascular disease therapeutics. J. Cardiovasc. Pharmacol. 2007, 50:112-119.
19. Wang G., Lai F.M., Lai K.B., Chow K.M., Kwan C.H., Li K.T., Szeto C.C. Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy. Diabetologia 2008, 51:1062-1067.
20. Yamamoto K., Ohishi M., Katsuya T., Ito N., Ikushima M., Kaibe M., Tatara Y., Shiota A., Sugano S., Takeda S., Rakugi H., Ogihara T. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 2006, 47:718-726.
21. Zhou L., Zhang R., Yao W., Wang J., Qian A., Qiao M., Zhang Y., Yuan Y. Decreased expression of angiotensin-converting enzyme 2 in pancreatic ductal adenocarcinoma is associated with tumor progression. Tohoku J. Exp. Med. 2009, 217:123-131.
22. Feng Y., Wan H., Liu J., Zhang R., Ma Q., Han B., Xiang Y., Che J., Cao H., Fei X., Qiu W. The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol. Rep. 2010, 23:941-948.
23. Lovren F., Pan Y., Quan A., Teoh H., Wang G., Shukla P.C., Levitt K.S., Oudit G.Y., Al-Omran M., Stewart D.J., Slutsky A.S., Peterson M.D., Backx P.H., Penninger J.M., Verma S. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H1377-1384.
24. Zhang R., Wu Y., Zhao M., Liu C., Zhou L., Shen S., Liao S., Yang K., Li Q., Wan H. Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2009, 297:L631-640.
25. Shi W., Meng Z., Chen Z., Luo J., Liu L. Proteome analysis of human pancreatic cancer cell lines with highly liver metastatic potential by antibody microarray. Mol. Cell Biochem. 2011, 347:117-125.
26. Hosono J., Narita T., Kimura N., Sato M., Nakashio T., Kasai Y., Nonami T., Nakao A., Takagi H., Kannagi R. Involvement of adhesion molecules in metastasis of SW1990, human pancreatic cancer cells. J. Surg. Oncol. 1998, 67:77-84.
27. Koong A.C., Mehta V.K., Le Q.T., Fisher G.A., Terris D.J., Brown J.M., Bastidas A.J., Vierra M. Pancreatic tumors show high levels of hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48:919-922.
28. Duffy J.P., Eibl G., Reber H.A., Hines O.J. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol. Cancer 2003, 2:12.
29. Vaupel P., Thews O., Kelleher D.K. Pancreatic tumors show high levels of hypoxia: regarding Koong et al. IJROBP 2000;48:919-922. Int. J. Radiat. Oncol. Biol. Phys. 2001, 50:1099-1100.
30. Paizis G., Tikellis C., Cooper M.E., Schembri J.M., Lew R.A., Smith A.I., Shaw T., Warner F.J., Zuilli A., Burrell L.M., Angus P.W. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 2005, 54:1790-1796.
31. Burrell L.M., Risvanis J., Kubota E., Dean R.G., MacDonald P.S., Lu S., Tikellis C., Grant S.L., Lew R.A., Smith A.I., Cooper M.E., Johnston C.I. Myocardial infarction increases ACE2 expression in rat and humans. Eur. Heart J. 2005, 26:369-375. (discussion 322-364).
32. Young S.D., Marshall R.S., Hill R.P. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc. Natl. Acad. Sci. USA 1988, 85:9533-9537.
33. Rofstad E.K., Rasmussen H., Galappathi K., Mathiesen B., Nilsen K., Graff B.A. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res. 2002, 62:1847-1853.
34. Helczynska K., Kronblad A., Jogi A., Nilsson E., Beckman S., Landberg G., Pahlman S. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res. 2003, 63:1441-1444.
35. Fendrich V., Chen N.M., Neef M., Waldmann J., Buchholz M., Feldmann G., Slater E.P., Maitra A., Bartsch D.K. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 2010, 59:630-637.
36. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
37. Rothenberg M.L., Moore M.J., Cripps M.C., Andersen J.S., Portenoy R.K., Burris H.A., Green M.R., Tarassoff P.G., Brown T.D., Casper E.S., Storniolo A.M., Von Hoff D.D. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. 1996, 7:347-353.
38. Lindberg H., Nielsen D., Jensen B.V., Eriksen J., Skovsgaard T. Angiotensin converting enzyme inhibitors for cancer treatment?. Acta Oncol. 2004, 43:142-152.
39. Ocaranza M.P., Godoy I., Jalil J.E., Varas M., Collantes P., Pinto M., Roman M., Ramirez C., Copaja M., Diaz-Araya G., Castro P., Lavandero S. Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 2006, 48:572-578.
40. Igase M., Kohara K., Nagai T., Miki T., Ferrario C.M. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertens. Res. 2008, 31:553-559.